Skip to main content
Home > The Daily Extra > Company News

Chronological Index of : Company News

 Current Issue
  • COMPANY NEWS: AbbVie forecasts $3B run rate for Viekira Pak

    On its 4Q14 earnings call on Friday, AbbVie Inc. (NYSE:ABBV) forecast that it would achieve a global annualized sales run rate of $3 billion for HCV drug regimen Viekira Pak paritaprevir/ritonavir/ombitasvir/dasabuvir …

    Published on 1/30/2015
  • COMPANY NEWS: Biogen up as earnings top estimates

    Biogen Idec Inc. (NASDAQ:BIIB) jumped $35.58 (10%) to $388.83 on Friday, reaching an all-time high after its 4Q14 earnings beat the Street. The company's 4Q14 non-GAAP diluted EPS was $4.09, up 75% from $2.34 in the …

    Published on 1/30/2015
  • COMPANY NEWS: FDA approves Vyvanse for binge-eating disorder

    FDA approved an sNDA under Priority Review for Vyvanse lisdexamfetamine dimesylate (S-877489) from Shire plc (LSE:SHP; NASDAQ:SHPG) to treat binge-eating disorder in adults. The agency said Vyvanse is the only FDA-…

    Published on 1/30/2015
  • COMPANY NEWS: ImmunoGen gains on 4Q14 earnings

    ImmunoGen Inc. (NASDAQ:IMGN) rose $1.43 (23%) to $7.63 on Friday after reporting 4Q14 earnings that beat analysts' estimates. The company has yet to regain ground lost in mid-December after Roche (SIX:ROG; OTCQX:RHHBY) …

    Published on 1/30/2015
  • COMPANY NEWS: Valeant makes $296M bid for Provenge

    Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) made a $296 million cash bid to acquire selected assets of bankrupt Dendreon Corp. (Pink:DNDNQ), including global rights to prostate cancer vaccine Provenge…

    Published on 1/30/2015
  • COMPANY NEWS: Alexion founder Bell to retire as CEO

    Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) said principal founder Leonard Bell will retire as CEO, effective April 1, while remaining chairman.COO David Hallal, who joined Alexion in 2006, will succeed Bell as CEO. …

    Published on 1/29/2015
  • COMPANY NEWS: Biogen, TIGET in hemophilia gene therapy tie-up

    Biogen Idec Inc. (NASDAQ:BIIB) started a collaboration with Fondazione Telethon (Milano, Italy) and Ospedale San Raffaele (Milano, Italy) to develop gene therapies to treat hemophilia A and B.Biogen will pay the San …

    Published on 1/29/2015
  • COMPANY NEWS: FDA approves Imbruvica for Waldenstrom's

    FDA approved an sNDA for Imbruvica ibrutinib from Pharmacyclics Inc. (NASDAQ:PCYC) and the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) to treat Waldenstrom's macroglobulinemia, well ahead of its April 17 …

    Published on 1/29/2015
  • COMPANY NEWS: Merck KGaA returns Sym004 rights to Symphogen

    Symphogen A/S (Copenhagen, Denmark) regained exclusive, worldwide rights to Sym004 from Merck KGaA (Xetra:MRK), unwinding a 2012 deal. Both Merck and Symphogen said the decision was not related to new safety or efficacy…

    Published on 1/29/2015
  • COMPANY NEWS: Applied Molecular Transport, Janssen strike IBD deal

    Applied Molecular Transport LLC (South San Francisco, Calif.) granted the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) exclusive worldwide rights to an undisclosed preclinical oral candidate to treat …

    Published on 1/28/2015
  • COMPANY NEWS: State Medicaid group chooses Viekira Pak

    Missouri's Medicaid agency said it will make Viekira Pak from AbbVie Inc. (NYSE:ABBV) its preferred regimen to treat HCV in exchange for undisclosed rebates. Missouri is part of a consortium of 24 states plus the …

    Published on 1/28/2015
  • COMPANY NEWS: Biogen, Google to begin MS study

    Biogen Idec Inc. (NASDAQ:BIIB) and the Google X Life Sciences innovative research unit of Google Inc. (NASDAQ:GOOG) have established a collaboration to study the symptoms and progression of multiple sclerosis (MS). The …

    Published on 1/27/2015
  • COMPANY NEWS: Express Scripts' Miller says HCV deals will save billions

    Steve Miller, SVP and CMO of Express Scripts Holding Co. (NASDAQ:ESRX), wrote in a blog post that the PBM's deal last month with AbbVie Inc. (NYSE:ABBV) covering HCV treatment Viekira Pak will save its clients "more …

    Published on 1/27/2015
  • COMPANY NEWS: Sandoz moves to dismiss Amgen patent suit

    The Sandoz unit of Novartis AG (NYSE:NVS; SIX:NOVN) filed a motion in the U.S. District Court for the Northern District of California seeking an order to dismiss patent infringement and related claims from Amgen Inc. (…

    Published on 1/27/2015
  • COMPANY NEWS: FDA approves Symplmed's Prestalia combo for hypertension

    Symplmed Pharmaceuticals LLC (Cincinnati, Ohio) said FDA approved an NDA for Prestalia to treat hypertension. The company plans to launch the fixed-dose combination of perindopril arginine plus amlodipine besylate this …

    Published on 1/26/2015
  • COMPANY NEWS: Pharmas pitch in on GAVI initiative

    The Global Alliance for Vaccine Immunization (GAVI) announced commitments from private sector partners including Pfizer Inc. (NYSE:PFE), GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), the Janssen Pharmaceuticals Inc. unit of …

    Published on 1/26/2015
  • COMPANY NEWS: Voucher puts alirocumab ahead in PCSK9 race

    FDA accepted and granted Priority Review to a BLA for Praluent alirocumab from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Sanofi (Euronext:SAN; NYSE:SNY) to treat hypercholesterolemia.Praluent's PDUFA date is July…

    Published on 1/26/2015
  • COMPANY NEWS: Array acquires BRAF inhibitor from Novartis

    Array BioPharma Inc. (NASDAQ:ARRY) surged $2.06 (41%) to $7.11 after gaining worldwide rights to encorafenib (LGX818) from Novartis AG (NYSE:NVS; SIX:NOVN). Array said it will make a "de minimis" upfront payment to …

    Published on 1/23/2015
  • COMPANY NEWS: CHMP recommends Sivextro for ABSSSI

    EMA's CHMP recommended marketing authorization of oral and IV Sivextro tedizolid from Merck & Co. Inc. (NYSE:MRK) to treat acute bacterial skin and skin structure infections (ABSSSI) in adults. CHMP said the …

    Published on 1/23/2015
  • COMPANY NEWS: FDA approves Novartis' meningitis B vaccine

    FDA approved Bexsero from Novartis AG (NYSE:NVS; SIX:NOVN) to prevent invasive meningococcal disease caused by serogroup B in individuals aged 10-25. The multicomponent meningococcal serogroup B vaccine had breakthrough…

    Published on 1/23/2015
  • COMPANY NEWS: Medicines Co. scores CHMP hat trick

    EMA's CHMP recommended marketing authorization of three candidates from The Medicines Co. (NASDAQ:MDCO): Kengrexal cangrelor to reduce thrombotic cardiovascular events, Orbactiv oritavancin to treat acute bacterial skin…

    Published on 1/23/2015
  • COMPANY NEWS: FDA panel backs Astellas-Basilea antifungal

    FDA's Anti-Infective Drugs Advisory Committee on Thursday backed approval of Cresemba isavuconazonium (BAL8557) from Astellas Pharma Inc. (Tokyo:4503) to treat invasive aspergillosis and mucormycosis in adults. The …

    Published on 1/22/2015
  • COMPANY NEWS: NICE now backs Jardiance for Type II diabetes

    The U.K.'s NICE issued a final appraisal determination (FAD) recommending Jardiance empagliflozin (BI-10773) from partners Boehringer Ingelheim GmbH (Ingelheim, Germany) and Eli Lilly and Co. (NYSE:LLY) to treat Type II…

    Published on 1/22/2015
  • COMPANY NEWS: Novo's liraglutide gets CHMP nod for obesity

    Novo Nordisk A/S (CSE:NVO; NYSE:NVO) said EMA's CHMP recommended marketing authorization of its Saxenda liraglutide for chronic weight management as an adjunct to diet and exercise in obese adults or in overweight …

    Published on 1/22/2015
  • COMPANY NEWS: Celgene, Zymeworks partner on bispecific antibodies

    Celgene Corp. (NASDAQ:CELG) and Zymeworks Inc. (Vancouver, B.C.) entered a multi-year collaboration to develop and commercialize bispecific antibodies using Zymeworks' Azymetric platform. Celgene will receive options to…

    Published on 1/21/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993